FDA clears J&J’s oral psoriasis drug Icotyde
Johnson & Johnson said the US Food and Drug Administration has approved Icotyde (icotrokinra) for moderate-to-severe plaque psoriasis in adults and in pediatric patients age 12 and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. The March 18, 2026 approval gives J&J a newly launched oral IL-23 receptor antagonist, which the company is positioning as the first targeted oral peptide in the category. The decision follows Phase 3 data from the ICONIC program — including ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 — in about 2,500 patients, with the company saying the drug met all primary endpoints across all four trials. In head-to-head studies, about 70% of patients achieved Investigator’s Global Assessment (IGA) 0/1 and 55% reached PASI 90 at week 16; later readouts also compared icotrokinra with deucravacitinib. (investor.jnj.com; PharmaShots)
Why it matters: While this is a human medicine approval, veterinary professionals tracking dermatology, immunology, and regulatory trends may see it as another sign that cytokine-targeted therapies continue to move toward more convenient oral formats. It also lands in a competitive psoriasis market: Takeda has reported late-stage data for oral TYK2 inhibitor zasocitinib and plans regulatory submissions starting in its fiscal 2026, underscoring how developers are competing not just on efficacy, but on route of administration, speed, durability, age-label breadth, and positioning earlier in the treatment pathway. For clinicians and industry teams, that broader competitive context matters because it shows how quickly oral immune-targeted options are evolving. (PharmaShots; investor.jnj.com)
What to watch: Watch for launch uptake, payer access, additional safety experience in broader real-world use, and whether J&J can expand icotrokinra into other inflammatory indications already under study, including psoriatic arthritis, ulcerative colitis, and Crohn’s disease. Also watch the competitive oral psoriasis field as other late-stage agents move toward filing. (drugs.com; PharmaShots)